Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Junqing (Frank) Xie who has been awarded the Stanley A. Edlavitch Award from The International Society for Pharmacoepidemiology (ISPE).

Frank Xie receives his award from ISPE
Anton Pottegård (l), Chair, of the Scientific Program Committee of the 38th ISPE presents the Stanley A. Edlavitch Award to Junqing (Frank) (r)

The award, named after the Society's first executive director, is presented each year to the student/Post-Doc who submits the most highly rated abstract for presentation at the meeting.

Frank's paper is called: Genetic risk and incident venous thromboembolism in middle-aged and older adults following Covid-19 vaccination.

The research, pre-printed in medRxiv, set out to explore whether the genetic risk for venous blood clots, aka venous thromboembolism (VTE) changes following the Covid-19 vaccination. They discovered that known genetic variants associated with VTE in the general population remain associated with the risk of VTE after Covid-19 vaccination. This genetic risk appeared unlikely to be altered by large-scale vaccination.

Frank was presented with the award at the ICPE 2022 on Saturday, August 28 in Copenhagen.

On receiving the award Frank said: "This finding built on large Real-World and Biobank genetic data deeps our understanding of the safety of Covid-19 vaccines, showing promise of accelerating interdisciplinary research in NDORMS, University of Oxford."

Similar stories

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.

Study reveals new evidence on rare blood-clotting condition after covid-19 vaccination

Researchers from NDORMS at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.

NDORMS contributes to new UK research to tackle monkeypox outbreak

The UK’s efforts to tackle the monkeypox outbreak will receive a huge boost with the creation of a new research consortium and a new study to study vaccine effectiveness.

World Osteoporosis Day 2022

A bone-healthy lifestyle is vital for strong bones and a mobile, fracture-free future. On World Osteoporosis Day, we are sharing advice from the International Osteoporosis Foundation (IOF), on putting your bone health first.

Mathematician boosts data science research at the Kennedy Institute

Welcome to Yang Luo who has joined the Kennedy Institute as the Principal Investigator of the Luo Group. Her lab is leading the investigation into how genetic variations contribute to diseases of the immune system.